Zydus Cadila gets USFDA nod for migraine drug

Top Stories

»	India’s manufacturing sector strengthens further in recent quarters with robust GVA growth
»	Precious metals’ prices dip over dollar gains
»	RBI proposes ban on 3rd‑party sales incentives to bank staff to curb mis-selling
»	Sensex, Nifty open in red; IT index dips 3.58 pc
»	RBI's 'Financial Literacy Week' to stress KYC awareness in Gujarat and UTs

SME Times News Bureau | 20 Jun, 2017
Pharma major Zydus Cadila on Monday said it has received the final approval from the US Food and Drug Administration (FDA) to sell Eletriptan Hydrobromide tablets, used in the treatment of migraine.

According to the company, the drug with strengths 20mg and 40mg will be produced at the group's formulations manufacturing facility at the Pharma SEZ (special economic zone) in Ahmedabad.

"The group now has more than 120 approvals and has so far filed over 300 ANDAs (abbreviated new drug applications ) since the commencement of the filing process in FY 2003-04," the firm said in a regulatory filing with the BSE.